Cognition Therapeutics (CGTX) Life Sciences Investor Forum summary

Key program updates

• Lead drug zervimesine (CT1812) targets toxic oligomers in synapses, showing efficacy in both Alzheimer's and Lewy body dementia (LBD).

• Fast-track approval for Alzheimer's and pursuing similar regulatory pathways for LBD.

• Dry age-related macular degeneration program was discontinued to focus resources on neurodegeneration trials.

• SHIMMER trial in LBD and SHINE trial in Alzheimer's both demonstrated strong safety and efficacy profiles.

• Consistent efficacy observed across two diseases, with no ARIA and once-daily oral administration.

Clinical trial results

• SHIMMER Phase II trial in LBD showed 91% slowing of disease progression and significant improvements in neuropsychological and functional measures.

• Caregiver distress reduced by 114% and cognitive decline slowed by up to 85% in LBD patients.

• SHINE trial in Alzheimer's showed 39–70% slowing in cognitive decline, with up to 95% slowing in patients with low p-tau.

• Both trials reported safety profiles comparable to placebo, with no major adverse events linked to the drug.

• Movement and daily living activities in LBD patients improved, with 62% slowing in movement deterioration.

Financial and strategic outlook

• $22 million in cash as of last September, with an update expected in the March 10-K filing.

• $53 million in grant funding, all from domestic NIH/NIA sources.

• Actively seeking partners for Phase III funding, aiming for non-dilutive or cash funding.

• Granted an additional six months to regain NASDAQ compliance; confident in achieving this through upcoming milestones.

• ATM facility remains in place, with updates on usage to be provided in quarterly filings.